Understanding Scarring Alopecia: Causes, Symptoms, and Treatment Options

A Complete Guide to Scarring Alopecia – Updated for 2026

What Is Scarring Alopecia?

Scarring alopecia, also called cicatricial alopecia, is a group of hair loss conditions in which inflammation permanently destroys hair follicles, replacing them with scar tissue. Once a follicle is scarred, it cannot regrow hair. Early diagnosis is therefore critical: the sooner the inflammatory process is controlled, the more hair can be preserved.

Scarring alopecia affects men and women of all ages and ethnicities, though specific subtypes are more prevalent in particular groups. It accounts for roughly 3–7% of hair loss cases seen in specialist clinics worldwide, and its overall incidence is rising, particularly for frontal fibrosing alopecia (FFA), which is now the most common form diagnosed globally.

Common Types of Scarring Alopecia

Frontal Fibrosing Alopecia (FFA)

FFA is characterized by a slowly progressive recession of the frontal and temporal hairline, frequently accompanied by the loss of eyebrows and eyelashes. The skin along the receding hairline often appears pale, slightly shiny, and mildly inflamed, a band-like zone that distinguishes FFA from ordinary pattern hair loss.

First described by Dr Steven Kossard in 1994, FFA was initially thought to affect only postmenopausal women. Today it is recognized far more broadly:

• Postmenopausal women remain the most commonly affected group, but premenopausal women, men, and adolescents are also diagnosed.
• Men with FFA typically present at a younger age and are often misdiagnosed. Their early signs (beard thinning, sideburn recession, eyebrow loss) can be mistaken for androgenetic alopecia or alopecia areata. Facial papules and body hair loss also appear more frequently in men. A 2025 systematic review in JAAD Reviews highlighted these important sex-based differences in presentation and management.
• FFA is now the most common primary cicatricial alopecia in clinical practice, a shift formally noted in a landmark April 2026 CME series published by the Journal of the American Academy of Dermatology.

FFA is closely related to lichen planopilaris (LPP) and is widely regarded as a clinical variant of it.

Lichen Planopilaris (LPP)

LPP affects hair follicles across the scalp, causing small, red, flat-topped bumps and scaling around individual hairs. As inflammation progresses, patches of permanent hair loss develop. Itching, burning, and tenderness are common symptoms.

Central Centrifugal Cicatricial Alopecia (CCCA)

CCCA begins at the crown of the scalp and spreads outward in a centrifugal pattern. It disproportionately affects women of African descent and has been associated with certain hairstyling practices, though genetic factors also play a role. Early recognition matters greatly, as loss can become extensive before symptoms become obvious.

What Causes Scarring Alopecia?

The precise causes vary by subtype, but in most cases a combination of immune, genetic, hormonal, and environmental factors converges to trigger destructive inflammation around hair follicles.

Autoimmune Mechanisms

In FFA and LPP, the immune system launches a lymphocytic attack on the hair follicle’s outer root sheath, disrupting the follicle’s normal “immune privilege,” a mechanism that usually shields it from immune surveillance. Once this breaks down, chronic inflammation leads to fibrosis (scarring).

Genetic Predisposition

A genetic link in FFA, long suspected from familial cases, has now been confirmed through genetic studies. Specific human leukocyte antigen (HLA) class I alleles, including HLA-DR1 and HLA-B7, have been implicated.

Hormonal Factors

Oestrogen depletion is thought to be significant in postmenopausal women with FFA, which helps explain why 5-alpha reductase inhibitors (which modulate androgens) are among the most widely used systemic treatments.

Environmental Triggers: The Sunscreen and Cosmetics Debate

One of the most active areas of research involves the role of leave-on facial products, particularly sunscreens and moisturizers. Studies have consistently found that FFA patients report higher rates of facial sunscreen use than control groups, and a systematic review and meta-analysis confirmed a statistically significant association even after adjusting for age and sex.

The leading hypothesis is that certain ingredients (including titanium dioxide, oxybenzone, and fragrance allergens such as linalool) penetrate the follicular infundibulum and trigger a lichenoid immune reaction. However, the relationship is not straightforward: some research suggests that increased sunscreen use in FFA patients may partly reflect their existing actinic (sun) damage rather than being a direct cause. As of 2025–2026, the evidence remains associative rather than causal, and no single ingredient has been proven to cause FFA.

Dermatologists currently advise patients with active FFA to:

• Avoid applying leave-on facial products directly along the hairline margin
• Be cautious with fragrance-containing cosmetics and hair products in the frontotemporal region
• Discuss patch testing with their dermatologist if contact allergy is suspected

Associated Conditions

FFA is frequently found alongside other conditions, including rosacea (affecting 15–61% of FFA patients), thyroid disorders, and androgenetic alopecia. These associations may reflect shared immune or hormonal pathways and should be considered during clinical evaluation.

Signs and Symptoms

While symptoms differ between subtypes, common warning signs of scarring alopecia include:

• A slowly receding hairline, often with a pale or slightly shiny band of skin at the margin (characteristic of FFA)
• Loss of eyebrows and/or eyelashes — a hallmark of FFA, affecting the majority of patients
• Itching, burning, or tenderness on the scalp
• Redness (erythema) or scaling around individual follicle openings
• Small facial papules (skin-coloured bumps on the face) — more common in men with FFA
• Patchy hair loss in other body areas (beard, body hair)
• In CCCA: thinning beginning at the crown and spreading outward

Because these conditions progress slowly and can be asymptomatic early on, many people do not seek help until significant follicle destruction has already occurred. If you notice any of these signs, early specialist review is strongly recommended.

How Is Scarring Alopecia Diagnosed?

Diagnosis requires a thorough assessment by a specialist in hair loss. This typically involves:

• Detailed medical history, including family history, medications, and skincare product use
• Clinical examination of the scalp, hairline, eyebrows, and other affected areas
• Trichoscopy — dermoscopy of the scalp, which can reveal perifollicular scaling, erythema, and follicular dropout patterns characteristic of specific subtypes
• Scalp biopsy — often essential for definitive diagnosis; a small sample of affected scalp is examined histologically to identify the pattern of inflammation and fibrosis

Trichoscopy has become an increasingly important non-invasive diagnostic tool and is now standard of care in specialist hair clinics.

Treatment Options in 2026

There is currently no cure for scarring alopecia. The primary goals of treatment are to halt or slow progression and reduce symptoms. Treatments are most effective when started early, before extensive scarring has occurred.

Current Standard Treatments

The SOFFIA 2024 consensus — the first large-scale international expert consensus on FFA treatment, involving 69 hair experts across six continents — established the following general framework (published in the Journal of the European Academy of Dermatology and Venereology, 2026):

• Highly potent topical corticosteroids are the preferred first-line topical therapy for active FFA
• Intralesional corticosteroid injections are recommended specifically for FFA-related eyebrow loss
• 5-Alpha reductase inhibitors (such as finasteride or dutasteride) are the most widely endorsed systemic treatment, particularly for slowing hairline progression
• Hydroxychloroquine (an antimalarial with immune-modulating effects) is a commonly used second systemic option
• Topical tacrolimus (a calcineurin inhibitor) is used as a steroid-sparing alternative
• Low-dose isotretinoin is the preferred treatment for facial papules associated with FFA
• Topical and low-dose oral minoxidil can help improve overall hair thickness alongside anti-inflammatory treatments

A Spanish working group consensus (January 2026) and the JAAD’s two-part CME series (April 2026) reinforce these approaches and provide additional clinical detail on monitoring and sequencing.

Emerging Therapies: JAK Inhibitors

Baricitinib — a JAK inhibitor already approved for other autoimmune conditions is currently in clinical trials for FFA. A mid-trial update presented at the 2025 Fall Clinical Dermatology Conference and published in June 2026 examined its impact on disease activity and progression. FFA has generally been resistant to standard treatments, and JAK inhibitors represent one of the most promising new avenues, given their targeted mechanism of action in immune-mediated hair loss.

Non-Surgical Hair Replacement

For many people living with scarring alopecia, the practical reality is managing the visible effects of hair loss while medical treatment works to prevent further progression. Women’s on-surgical hair replacement systems as well as men’s non-surgical hair systems can restore a full hairline and the appearance of healthy hair without surgery or further scalp trauma. This option:

• Is suitable for both men and women at any stage of hair loss
• Allows clients to maintain their normal social and professional lives
• Can be combined with ongoing medical treatment
• Provides immediate, visible results while longer-term therapies take effect

Importantly, non-surgical solutions also support psychological wellbeing: the emotional impact of visible hair and eyebrow loss is significant, and restoring the appearance of a natural hairline can meaningfully improve self-confidence and quality of life.

Frequently Asked Questions

Seeking Help

If you are concerned about a receding hairline, loss of eyebrows, or any of the symptoms described here, seek an assessment from a specialist hair loss professional as early as possible. Scarring alopecia is diagnosed on clinical and histological grounds, and prompt treatment gives the best chance of limiting permanent loss.

At Transitions member hair replacement studios and clinics, hair loss professionals work one-on-one with clients across all types of hair loss, including scarring alopecia. Today’s non-surgical hair replacement solutions are designed to restore your appearance and confidence while you navigate medical care because looking like yourself matters, every day.